Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)cohort · 2024 · 1 citations
2Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical StudyLate-Phase Clinical Trial · 2026
3GLIMSI: A real-world, multicenter study assessing the effectiveness and safety of Sitagliptin + Glimepiride + Metformin FDC in Indian patients with Type 2 diabetesRetrospective Study · 2026
4Usage of Glimepiride and Metformin Combination in Type 2 Diabetes Patients with Established Complications in Indian Settings2024 · 3 citations
5A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial2024 · 10 citations

More from Journal of Diabetes

More from Institute of Physics, Bhubaneshwar